STAT5B as a Potential Target for Anti-Cancer Medication (image) University of Veterinary Medicine -- Vienna Share Print E-Mail Caption a) Patients with an activating STAT5B mutation display a suppressed interferon response, which promotes the development and growth of leukemia cells. b) In the STAT5B-deficient leukemia mouse model, the increased interferon response led to a suppression of malignant leukemia cells. This reveals STAT5B as a potential target for anti-cancer medication. Credit Institute of Pharmacology and Toxicology/Vetmeduni Vienna Usage Restrictions None Share Print E-Mail Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.